BSX vs SOLV vs MDT Stock Comparison

Boston Scientific, Solventum and Medtronic Prices as of Nov 13, 2026 Peers: Industry group
BSX Boston Scientific Corp
$44.34 +3.1% 1M -57.8% 1Y
Market cap
$64.09B
P/E
18.3x
Revenue (TTM)
$21.07B
Div. yield
–
Medical Devices Healthcare
2 wins
SOLV Solventum Corp
$89.05 +2.0% 1M +18.4% 1Y
Market cap
$15.27B
P/E
97.9x
Revenue (TTM)
$8.16B
Div. yield
–
Medical Devices Healthcare
2 wins
MDT Medtronic plc
$102.86 +9.2% 1M +7.0% 1Y
Market cap
$132.41B
P/E
15.1x
Revenue (TTM)
$37.10B
Div. yield
0.03%
Medical Devices Healthcare
7 wins

Head to Head

11 decided of 12

Medtronic leads on 7 of the 12 questions below (Medtronic 7, Solventum 2, Boston Scientific 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionBSXSOLVMDTLeader
Larger companyMarket capitalisation $64.09B $15.27B $132.41B MDT
Cheaper on earningsLower P/E, profitable companies only 18.3x 97.9x 15.1x MDT
Cheaper on forward earningsLower price / next fiscal year consensus EPS 14.5x 12.8x 18.5x SOLV
Faster revenue growthRevenue growth, trailing twelve months +8.9% -2.8% +12.8% MDT
More profitableNet margin, trailing twelve months 16.6% 1.9% 23.6% MDT
Better return on capitalReturn on invested capital 9.9% 4.2% 11.7% MDT
Less leveragedLower net debt / EBITDA 2.1x 4.7x 1.2x MDT
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.03% –
Better 1-year returnPrice return, last 12 months -57.8% +18.4% +7.0% SOLV
Better 5-year returnAnnualised price return, 5 years +1.1%/yr — -2.9%/yr BSX
Less volatileAnnualised volatility, 1 year 41.5% 30.1% 25.6% MDT
Higher overall scoreMean of the five percentile scores vs peers 68/100 51/100 63/100 BSX

Percentile Scorecard

BSXSOLVMDT

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBSXSOLVMDT
Valuation 87 #33 of 243 70 #74 of 243 87 #32 of 243
Growth 68 #73 of 228 3 #221 of 228 35 #149 of 228
Profitability 91 #20 of 222 71 #66 of 222 98 #6 of 222
Financial Health 43 #142 of 248 15 #210 of 248 50 #124 of 248
Shareholder Returns 48 #82 of 158 94 #10 of 158 43 #90 of 158
Overall 68 51 63
  • BSX ranked among 252 companies in Medical Devices and Diagnostics
  • SOLV ranked among 252 companies in Medical Devices and Diagnostics
  • MDT ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBSXSOLVMDTSPY
1 month +3.1%+2.0%+9.2% -2.0%
3 months -14.5%+0.5%+12.7% -2.8%
6 months -15.8%+19.9%+35.1% +2.0%
Year to date -53.5%+12.4%+7.1% +10.6%
1 year -57.8%+18.4%+7.0% +12.2%
3 years -17.9%—+41.7% +68.1%
3 years, per year -6.4%—+12.3% +18.9%
5 years +5.4%—-13.8% +61.4%
5 years, per year +1.1%—-2.9% +10.1%
10 years +106.2%—+25.3% +248.5%
10 years, per year +7.5%—+2.3% +13.3%

Risk

MeasureBSXSOLVMDTSPY
Volatility, 1Y 41.5%30.1%25.6% 13.6%
Downside volatility, 1Y 47.7%29.3%22.3% 13.9%
Beta vs S&P 500, 1Y 0.260.610.14 1.00
Return / volatility, 1Y -1.390.610.27 0.90
Max drawdown, 5Y -61.6%-40.0%-41.2% -25.4%
From 52-week high -57.8%-3.7%-2.4% -3.2%
52-week high $104.98$92.45$105.35 $779.14
52-week low $41.57$62.49$73.75 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBSXSOLVMDT
P/E now vs peer median 18.3xmedian 26.5x 97.5xmedian 26.5x 15.0xmedian 26.5x
P/S now vs peer median 3.1xmedian 2.7x 1.9xmedian 2.7x 3.5xmedian 2.7x
EV/EBITDA now vs peer median 14.1xmedian 18.4x 20.3xmedian 18.4x 9.2xmedian 18.4x
P/FCF now vs peer median 19.3xmedian 25.4x 156.0xmedian 25.4x 10.3xmedian 25.4x
P/B now vs peer median 2.5xmedian 2.5x 3.1xmedian 2.5x 2.6xmedian 2.5x
PEG now vs peer median 0.42median 0.98 —median 0.98 1.85median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBSXSOLVMDT
Revenue $21.07B $8.16B $37.10B
Gross profit $14.57B $4.47B $24.23B
Operating income $3.93B $454.00M $11.28B
Net income $3.49B $156.00M $8.81B
Free cash flow $3.33B – $12.74B
R&D $2.16B $723.00M $4.93B
EPS (diluted) $2.41 $0.91 $6.81
Cash & equivalents $609.00M $451.00M $1.69B
Total debt $11.95B $5.07B $28.15B
Shares (diluted) 1.45B 170.80M 1.29B
Enterprise value $59.52B $12.98B $97.92B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBSXSOLVMDT
P/E 18.3x 97.5x 15.0x
P/FCF 19.3x 156.0x 10.3x
P/Operating cash flow 15.2x 48.8x 10.7x
P/S 3.1x 1.9x 3.5x
P/B 2.5x 3.1x 2.6x
P/Tangible book 3.4x 6.1x 3.2x
EV/EBITDA 14.1x 20.3x 9.2x
EV/EBIT 19.2x 43.5x 13.4x
EV/Revenue 3.6x 2.4x 4.1x
EV/FCF 22.7x – 11.9x
EV/Operating cash flow 17.9x 63.7x 12.2x
PEG (3Y EPS CAGR) 0.42 – 1.85

Growth

14 metrics
MetricBSXSOLVMDT
Revenue growth (1Y) 8.9% -2.8% 12.8%
Revenue CAGR (3Y) 15.3% – 6.7%
Gross profit growth (1Y) 9.8% -1.6% 13.1%
Gross profit CAGR (3Y) 15.1% – 6.0%
Operating income growth (1Y) 13.5% -79.3% 19.2%
Operating income CAGR (3Y) 22.1% – 5.7%
Net income growth (1Y) 25.5% -89.8% -17.8%
Net income CAGR (3Y) 41.7% – -4.4%
EPS growth (1Y) 29.2% -89.5% 24.7%
EPS CAGR (3Y) 44.0% – 8.1%
Operating cash flow growth (1Y) -8.5% -37.1% -22.3%
Operating cash flow CAGR (3Y) 21.6% – -6.7%
Free cash flow growth (1Y) -12.9% – 27.6%
Free cash flow CAGR (3Y) 25.2% – 6.7%

Profitability

14 metrics
MetricBSXSOLVMDT
Gross margin 69.1% 54.8% 65.3%
EBITDA margin 25.5% 11.9% 44.0%
Operating margin 18.7% 5.6% 30.4%
Pretax margin 17.3% 2.1% 29.2%
Net margin 16.6% 1.9% 23.6%
FCF margin 15.8% – 34.3%
Operating cash flow margin 20.1% 3.8% 33.2%
Return on equity 13.7% 3.3% 17.5%
Return on assets 7.7% 1.1% 9.5%
Return on invested capital 9.9% 4.2% 11.7%
Return on capital employed 10.0% 4.3% 13.9%
Asset turnover 0.5x 0.6x 0.4x
Cash conversion (OCF / net income) 1.2x 2.0x 1.4x
Stock comp / revenue 1.5% 2.1% 2.2%

Financial Health

11 metrics
MetricBSXSOLVMDT
Debt / assets 26.3% 35.8% 30.2%
Debt / equity 0.5x 1.1x 0.6x
Net debt / EBITDA 2.1x 4.7x 1.2x
Debt / FCF 3.6x – 2.2x
Liabilities / assets 43.1% 66.1% 45.5%
Equity / assets 56.9% 33.9% 54.5%
Interest coverage 10.5x – 8.9x
Current ratio 1.4x 1.0x 2.1x
Quick ratio 0.6x 0.5x 1.3x
Cash ratio 0.1x 0.1x 0.7x
Altman Z-score 3.03 1.85 3.32

Shareholder Returns

7 metrics
MetricBSXSOLVMDT
Dividend yield – – 2.8%
Net buyback yield -0.3% 2.7% -2.6%
Shareholder yield -0.3% 2.7% 0.1%
Payout ratio (earnings) – – 41.4%
Payout ratio (FCF) – – 28.7%
Dividend growth (1Y) – – 0.7%
Dividend CAGR (3Y) – – 0.7%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBSXSOLVMDT
Forward P/E 14.5xFY2026 12.8xFY2026 18.5xFY2026
EPS, next fiscal year $3.06FY2026 $6.93FY2026 $5.57FY2026
EPS growth, next FY 0.0%FY2026 +13.4%FY2026 +0.7%FY2026
EPS growth, the year after +8.2% +15.3% +7.4%
Revenue, next fiscal year $20.48BFY2026 $7.71BFY2026 $39.92BFY2026
Revenue growth, next FY +2.1%FY2026 -7.3%FY2026 +9.8%FY2026
Revenue growth, the year after -4.0% +5.8% -4.7%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBSXSOLVMDT
Held by institutions 90.5% 73.9% 85.1%
Institutions holding 1,484 882 2,128
Change in shares held, QoQ -0.7% -0.9% -0.2%
Institutions buying 738 370 1,015
Institutions selling 612 286 915
Buyers to sellers 1.21 1.29 1.11

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

BSXSOLVMDT
BSX 1.00 0.23 0.48
SOLV 0.23 1.00 0.44
MDT 0.48 0.44 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, BSX, SOLV and MDT?

Medtronic (MDT) is the largest by market capitalisation: Boston Scientific (BSX) $64.09B, Solventum (SOLV) $15.27B, Medtronic (MDT) $132.41B.

Which stock is cheaper, BSX, SOLV and MDT?

Medtronic (MDT) trades on the lowest price-to-earnings ratio (Boston Scientific (BSX) 18.3x, Solventum (SOLV) 97.9x, Medtronic (MDT) 15.1x). On next year's consensus earnings, Solventum (SOLV) is cheapest (Boston Scientific (BSX) 14.5x, Solventum (SOLV) 12.8x, Medtronic (MDT) 18.5x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Medtronic (MDT) grew revenue fastest over the trailing twelve months: Boston Scientific (BSX) +8.9%, Solventum (SOLV) -2.8%, Medtronic (MDT) +12.8%.

Which company is more profitable?

Medtronic (MDT) has the highest net margin (Boston Scientific (BSX) 16.6%, Solventum (SOLV) 1.9%, Medtronic (MDT) 23.6%). On return on invested capital, Medtronic (MDT) leads (Boston Scientific (BSX) 9.9%, Solventum (SOLV) 4.2%, Medtronic (MDT) 11.7%).

Which stock has performed better?

Over the past year Solventum (SOLV) returned the most: Boston Scientific (BSX) -57.8%, Solventum (SOLV) +18.4%, Medtronic (MDT) +7.0%. Over five years, Boston Scientific (BSX) compounded fastest (Boston Scientific (BSX) +1.1%/yr, Medtronic (MDT) -2.9%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Boston Scientific (BSX) 0.00%, Solventum (SOLV) 0.00%, Medtronic (MDT) 0.03%. Boston Scientific (BSX) and Solventum (SOLV) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Medtronic (MDT) has been the steadiest (Boston Scientific (BSX) 41.5%, Solventum (SOLV) 30.1%, Medtronic (MDT) 25.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, BSX, SOLV and MDT?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Medtronic (MDT) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.